tirzepatide surpass-4 Lilly's achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in trial Post Hoc Analysis of SURPASS-1
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27




























